Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement | Annals of the Rheumatic Diseases
Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance
Frontiers | Exploring the Mechanism of Indigo Naturalis in the Treatment of Ulcerative Colitis Based on TLR4/MyD88/NF-κB Signaling Pathway and Gut Microbiota | Pharmacology
Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowe
Advances in Clinical and Experimental Medicine
Frontiers | Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study | Medicine
Frontiers | Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring | Pharmacology
Frontiers | The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges | Immunology
Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis | BMJ Open Gastroenterology
2017 European Ulcerative Colitis Guidelines - Diagnosis - Part One of Two Parts - Page 11 of 11 - Tom Wade MD
The influence of cytokines on the complex pathology of ulcerative colitis - ScienceDirect
Frontiers | Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain? | Immunology
Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. - Document - Gale OneFile:
Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remi
Cureus | Patterns of Complementary and Alternative Medicine Use in Saudi Arabian Patients With Inflammatory Bowel Disease: A Cross-Sectional Study
Has infliximab influenced the course and prognosis of acute severe ulc | BTT
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis | BMJ Open Gastroenterology
Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany - Clinical Therapeutics
KoreaMed Synapse
Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial
The influence of cytokines on the complex pathology of ulcerative colitis - ScienceDirect
Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting | SpringerLink
PDF) Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice - ScienceDirect
Frontiers | The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies | Medicine
Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus - Digestive and Liver Disease
